Latest Molecular Diagnostics News

Page 1 of 3
INOVIQ has secured a validation agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer test, opening a potential route into the US laboratory-developed test market. The commercial opportunity remains conditional: Sonic has not committed to a licence, and validation is expected to run for 12 to 18 months.
Ada Torres
Ada Torres
2 Nov 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
Genetic Signatures has added a new AGM resolution seeking approval to issue up to 340.7 million shares and 129.7 million options under its proposed Microba merger. The all-scrip transaction remains non-binding and subject to further shareholder, court, regulatory and due diligence conditions.
Ada Torres
Ada Torres
23 Oct 2026
Genetic Signatures and Microba Life Sciences have agreed in principle to revise their proposed merger, reducing Microba shareholders’ post-deal ownership from about 67% to 60%. The change improves the position of existing GSS shareholders, but the transaction remains non-binding and subject to multiple approvals.
Victor Sage
Victor Sage
21 Oct 2026
Genetic Signatures says its existing directors will resign if BCAL nominees become a majority after the 28 October EGM. The company is also demanding clarity on whether BCAL intends to merge with GSS, pointing to the stark difference between the two companies’ cash runways.
Ada Torres
Ada Torres
16 Oct 2026
Genetic Signatures reduced its quarterly operating cash outflow to A$1.0 million after restructuring, while commercial testing began under its Danish hospital contract. The company is also advancing an all-scrip Microba merger, but faces a contested shareholder meeting later this month.
Ada Torres
Ada Torres
8 Oct 2026
Microba shareholders would own about 67% of an enlarged Genetic Signatures under a proposed all-scrip merger valued at approximately A$51 million. The deal combines roughly A$29.6 million of FY2026 revenue and identifies up to A$3 million in potential annual cost synergies, but remains subject to a long list of approvals.
Victor Sage
Victor Sage
22 Sept 2026
Pacific Edge is positioning Cxbladder for a Medicare-led recovery, but the company remains loss-making with NZ$7.8 million in net cash after a difficult FY26. The investment case now turns on final US coverage, test volumes and whether the enlarged balance sheet can carry the business to scale.
Ada Torres
Ada Torres
14 Sept 2026
Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.
Ada Torres
Ada Torres
26 Aug 2026
BCAL Diagnostics has increased its shareholding in Genetic Signatures to nearly a fifth, aiming to leverage infectious disease technology to complement its cancer detection portfolio.
Ada Torres
Ada Torres
26 Aug 2026
Genetic Signatures narrowed its FY2026 net loss by 30% to $14 million amid a strategic overhaul, signing a key 10-year supply deal with Denmark’s Hvidovre Hospital and resetting its US market approach.
Ada Torres
Ada Torres
25 Aug 2026
BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.
Ada Torres
Ada Torres
30 July 2026

Browse the archive

Full archive